We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STAN:LSEStandard Chartered PLC Analysis

Data as of 2026-06-28 - not real-time

£2,036.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Standard Chartered PLC is trading around 2,036 GBp, comfortably above its 20‑day (≈1,983) and 50‑day (≈1,913) moving averages, with the MACD histogram turning positive and the RSI sitting in the mid‑50s, indicating a healthy bullish momentum. The recent upgrade to Buy by Deutsche Bank, citing the bank’s superior positioning to capture rapid Asian wealth‑management growth, adds a strong catalyst, while the stock’s PE of 12.97 sits well below the industry average of 16.9, suggesting an undervalued valuation. A dividend yield of 2.23% and a modest payout ratio of under 30% further support the case for income‑seeking investors.
The fundamentals reinforce the technical outlook: revenue is expanding at roughly 8.6% year‑over‑year, operating margins are robust at ~44%, and the balance sheet shows ample liquidity with cash far exceeding debt. Low beta (≈0.61) and a diversified geographic footprint across Asia, Africa and the Middle East temper market‑wide volatility, though exposure to emerging‑market cycles and currency swings adds a medium‑level risk. Overall, the combination of attractive valuation, strong earnings profile, and positive sentiment makes the stock a compelling buy across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technical setup (price above SMA20/50, positive MACD histogram)
  • Deutsche Bank upgrade to Buy with target uplift
  • Attractive PE relative to industry peers

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained revenue growth and high operating margins
  • Undervalued valuation metrics and solid dividend yield
  • Strategic exposure to expanding Asian wealth‑management market

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong balance sheet with cash far exceeding debt
  • Diversified global footprint reducing reliance on any single market
  • Consistent dividend policy and low payout ratio indicating sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth8.60%
Profit Margin26.05%
P/E Ratio13.0
ROE10.11%
ROA0.59%
P/B Ratio1.4
Industry P/E16.9

Technical Analysis

TrendBullish
RSI57.4
Support£1,764.50
Resistance£2,278.00
MA 20£1,983.38
MA 50£1,913.43
MA 200£1,716.80
MACDBullish
VolumeDecreasing
Fear & Greed Index88.55

Valuation

Target Price£2,182.64
Upside/Downside7.20%
GradeUndervalued
TypeBlend
Dividend Yield2.23%

Risk Assessment

Beta0.61
Volatility34.57%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.